



## OPEN ACCESS

EDITED AND REVIEWED BY  
Michael Dougan,  
Massachusetts General Hospital and Harvard  
Medical School, United States

## \*CORRESPONDENCE

Mark A. Kroenke  
✉ mkroenke@amgen.com

## †PRESENT ADDRESS

Christina L. Zuch de Zafra,  
Nonclinical Sciences, Seagen, South  
San Francisco, CA, United States  
Michael Archer,  
Drug Safety and Pharmacovigilance,  
Atara Biotherapeutics, Thousand Oaks,  
CA, United States  
Gurleen Saini,  
Immunogenicity Characterization, Boehringer  
Ingelheim, Ridgefield, CT, United States

RECEIVED 01 June 2024

ACCEPTED 13 June 2024

PUBLISHED 20 June 2024

## CITATION

Kroenke MA, Manning MS, Zuch de Zafra CL,  
Zhang X, Cook KD, Archer M, Lolkema MP,  
Wang J, Hoofring S, Saini G, Aeffner F,  
Ahern E, Cabanas EG, Govindan R, Hui M,  
Gupta S and Mytych DT (2024) Corrigendum:  
Translatability of findings from cynomolgus  
monkey to human suggests a mechanistic  
role for IL-21 in promoting immunogenicity  
to an anti-PD-1/IL-21 mutein fusion protein.  
*Front. Immunol.* 15:1441999.  
doi: 10.3389/fimmu.2024.1441999

## COPYRIGHT

© 2024 Kroenke, Manning, Zuch de Zafra,  
Zhang, Cook, Archer, Lolkema, Wang,  
Hoofring, Saini, Aeffner, Ahern, Cabanas,  
Govindan, Hui, Gupta and Mytych. This is an  
open-access article distributed under the terms  
of the [Creative Commons Attribution License  
\(CC BY\)](#). The use, distribution or reproduction  
in other forums is permitted, provided the  
original author(s) and the copyright owner(s)  
are credited and that the original publication  
in this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein

Mark A. Kroenke<sup>1\*</sup>, Marta Starcevic Manning<sup>2</sup>,  
Christina L. Zuch de Zafra<sup>3†</sup>, Xinwen Zhang<sup>4</sup>, Kevin D. Cook<sup>5</sup>,  
Michael Archer<sup>6†</sup>, Martijn P. Lolkema<sup>7</sup>, Jin Wang<sup>2</sup>,  
Sarah Hoofring<sup>2</sup>, Gurleen Saini<sup>2†</sup>, Famke Aeffner<sup>3</sup>,  
Elizabeth Ahern<sup>8</sup>, Elena Garralda Cabanas<sup>9</sup>,  
Ramaswamy Govindan<sup>10</sup>, Mun Hui<sup>11</sup>, Shalini Gupta<sup>2</sup>  
and Daniel T. Mytych<sup>1</sup>

<sup>1</sup>Clinical Immunology, Amgen, Thousand Oaks, CA, United States, <sup>2</sup>Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States, <sup>3</sup>Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States, <sup>4</sup>Clinical Pharmacology, Modeling, and Simulation, Amgen, South San Francisco, CA, United States, <sup>5</sup>Pharmacokinetics and Drug Metabolism, Amgen, South San Francisco, CA, United States, <sup>6</sup>Global Safety, Amgen, Thousand Oaks, CA, United States, <sup>7</sup>Early Development, Amgen, Thousand Oaks, CA, United States, <sup>8</sup>Medical Oncology, Monash Health, Clayton, VIC, Australia, <sup>9</sup>Research Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain, <sup>10</sup>Division of Hematology and Oncology, Washington University Medical School, St. Louis, MO, United States, <sup>11</sup>Chris O'Brien Lifehouse, Camperdown, NSW, Australia

## KEYWORDS

PD-1, IL-21, immunogenicity, anti-drug antibodies, mutein, IgE

## A Corrigendum on

**Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein**

By Kroenke MA, Starcevic Manning M, Zuch de Zafra CL, Zhang X, Cook KD, Archer M, Lolkema MP, Wang J, Hoofring S, Saini G, Aeffner F, Ahern E, Cabanas EG, Govindan R, Hui M, Gupta S and Mytych DT (2024). *Front. Immunol.* 15:1345473. doi: 10.3389/fimmu.2024.1345473

## Error in Figure/Table

In the published article, there was an error in [Figure 2A](#) as published. The [Figure 2A](#) y-axis should read “Serum concentration (ng/mL)”. The corrected [Figure 2](#) is attached.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 2

IL-21 mutein domain enhanced the antibody response to 22D4 in cynomolgus monkeys. Cynomolgus monkeys were dosed with 5 mg/kg AMG 256, 5 mg/kg 22D4, or 5 mg/kg 22D4 plus 0.1 mg/kg recombinant human IL-21. (A) AMG 256 or 22D4 serum levels were measured over time in each of the 3 treatment groups. (B) The ADA response in each dosing group was assessed on day 15 and day 25 by UNISA. (C) Domain characterization was performed on AMG 256 dosed animals at the day 25 time point. Serum samples were pre-treated with either AMG 256 or 22D4 and re-tested in the antibody assay. Percent depletion indicates the signal change from the pre-treated sample relative to the untreated sample.